MedPath

Pomegranate Juice and Metabolic Syndrome

Not Applicable
Completed
Conditions
Metabolic Syndrome
Interventions
Other: pomegranate juice
Other: placebo
Registration Number
NCT02298621
Lead Sponsor
Urmia University of Medical Sciences
Brief Summary

The effect of pomegranate juice (PJ) intake on cardiovascular risks in subject with metabolic syndrome.

Detailed Description

The effect of pomegranate juice (PJ) intake on cardiovascular risks in subject with metabolic syndrome in shabestar.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • presence of ≥3 of the following diagnostic of MetS:

    • serum TGs of at least 150 mg/dL,
    • waist circumference of more than 102 cm (40 in) in men and more than 88 cm (35 in) in women,
    • high-density lipoprotein (HDL) level less than 40 mg/dL in men and less than 50 mg/dL in women,
    • blood pressure 135/85 mm Hg or higher, or
    • fasting glucose 100 mg/dL or Higher
Read More
Exclusion Criteria
  • liver cirrhosis,
  • chronic pancreatitis,
  • gastrointestinal or connective diseases,
  • kidney stones, or
  • renal failure,
  • alcohol Consumption,
  • having an allergy to pomegranate juice,
  • a change in diet,
  • the large increase in LDL so that required drug treatment.
  • use of statins of fibrates, corticosteroids, nitrates, acetyl-salicylic acid or other anti-platelet drugs, oral hypoglycemic drugs, nonsteroidal anti-inflammatory drugs, or drugs interfering with coagulation;
  • pregnancy or lactation in the past 6 mo, supplementation with vitamins or antioxidants
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
pomegranate juiceplacebopomegranate juice: 500 ml
placeboplacebosugar + aroma+ color: 500ml
pomegranate juicepomegranate juicepomegranate juice: 500 ml
placebopomegranate juicesugar + aroma+ color: 500ml
Primary Outcome Measures
NameTimeMethod
Change from baseline in values of metabolic syndrome components at 1 week1 week
Secondary Outcome Measures
NameTimeMethod
Change from baseline in values of insulin resistance (HOMA-IR), total cholesterol, LDL-C, VLDL-C and hs-CRP at 1 week1 weeks

Insulin resistance via HOMA-IR

Trial Locations

Locations (1)

Urmia University of Medical Sciences

🇮🇷

Urmia, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath